Psychedelic Therapy for Veterans: What the Research Shows

For a lot of veterans, the standard options feel exhausted. Talk therapy helps some people, some of the time. Medications manage symptoms but often leave the underlying trauma untouched. And the dropout rates from both are not encouraging. That is not a criticism of those approaches but it is simply where many veterans find themselves: still struggling, still searching, still looking for something that actually reaches the root of what they are struggling with.

That search has led more and more veterans toward psychedelic-assisted therapy. And the research, while still early in many respects, is giving real reason to pay attention.

Why Veterans Are Turning to Psychedelic Therapy

PTSD is not rare in the veteran population. Roughly 14 percent of VA patients carry a PTSD diagnosis, and the burden extends well beyond that number when you account for moral injury, depression, and substance use that often accompany combat trauma. The veteran suicide rate, adjusted for age and sex, sits 57 percent higher than the civilian rate. These are not abstract statistics as they represent real people, real families, and a system that has not yet found adequate answers.

Psychedelic therapy for veterans has emerged as a serious area of clinical inquiry precisely because of this gap. When existing treatments fall short, the case for exploring alternatives grows stronger, provided that exploration is grounded in safety, oversight, and honest expectations.

What the Research Actually Shows

The most substantial body of evidence involves MDMA-assisted therapy for PTSD. Phase 3 clinical trials found that after three MDMA-assisted sessions, 67 percent of participants no longer met the diagnostic criteria for PTSD. Separate data from peer-reviewed studies suggest that 86 percent of participants experienced a clinically meaningful benefit. These results represent a meaningful departure from what conventional treatments have historically achieved in this population.

Psilocybin has a somewhat different profile in the research. It has shown the most robust results in treatment-resistant depression, a condition that frequently co-occurs with PTSD in veterans. Studies from Johns Hopkins and others have demonstrated that a single supported psilocybin session can produce sustained symptom relief for up to 12 months. Trials specifically focused on psilocybin for PTSD are ongoing, and early qualitative research involving veterans found no serious adverse events and no participant dropouts.

Ketamine occupies a different legal space entirely. As the only FDA-approved psychedelic for a mental health condition, ketamine-assisted therapy is currently available through licensed clinics across the United States. For veterans dealing with treatment-resistant depression or suicidal ideation, it represents a legal, accessible option right now, not at some future point when legislation catches up.

One thing worth naming clearly: this is a field that is evolving quickly, and not everything is settled. The FDA declined to approve MDMA-assisted therapy in 2024, citing questions about safety data and the durability of results. That decision does not close the door on MDMA therapy. It means the research continues, with more rigor, and with careful attention to what the early trials may have missed. Honesty about that complexity is part of how we engage with this space.

The VA Is Finally Paying Attention

In December 2024, the Department of Veterans Affairs announced its first direct funding for a psychedelic-assisted therapy study in more than six decades. The study uses pharmaceutical-grade MDMA at VA facilities in Rhode Island and Connecticut, with strict safety protocols and regulatory oversight from both the FDA and DEA. The VA has since expanded participation to nine facilities across the country, including sites in Los Angeles, San Diego, Portland, and the Bronx.

This is significant not because it proves psychedelic therapy works for all veterans, but because it signals institutional recognition that the question is worth answering seriously. The VA’s framing is measured: this research is not an endorsement, and results will take years to emerge. But the fact that it is happening at all reflects how much the conversation has shifted.

Bipartisan congressional support has followed. The PATH Caucus and multiple legislative proposals have pushed for expanded funding, VA Centers of Excellence for innovative treatments, and pilot programs to prepare providers to deliver these therapies safely. Veteran-led advocacy organizations have been central to that movement, often serving as the most credible voices for reform precisely because they are speaking from lived experience.

What Makes Veteran Needs Different

Veterans with PTSD face a specific set of challenges that shape how psychedelic therapy should be approached. Military culture carries its own relationship to vulnerability, help-seeking, and trust in civilian providers. Many veterans have experienced moral injury, not just fear-based trauma, and the two require different therapeutic frameworks. Chronic pain, substance use, and psychiatric comorbidities are common. And the transition from military to civilian life introduces its own losses: identity, structure, community, and purpose.

Clinical researchers have noted that veterans engage in mental health treatment at lower rates than civilians, citing stigma, distrust, and a sense of alienation from providers who do not understand military culture. That context matters enormously in a therapy model where the relationship between the person and the guide is as important as the compound itself. A good fit is not a preference. It is a clinical variable.

This is where the preparation and integration stages of psychedelic therapy carry particular weight. In every clinical model showing meaningful results, the experience itself is embedded in a larger container: thorough screening beforehand, a structured session with trained support, and careful integration work afterward. Veterans who have worked with psychedelics outside of that container, without preparation and without integration, have had mixed and sometimes difficult outcomes. Structure is not incidental to these therapies. It is the point.

How JourneyŌM Supports Veterans

JourneyŌM is not a VA program, and we are not a clinical provider. What we are is a concierge-style guidance and matching service, built specifically to help seekers navigate a complex and sometimes overwhelming landscape with support at every step.

For veterans, that starts with understanding where you actually are. What is your mental health history? What medications are you on? Are there contraindications that need to be assessed before any substance-based work is appropriate? These are not gatekeeping questions. They are safety questions, and they are part of how we honor the seriousness of what you are considering.

From there, we match veterans with guides in our network who have experience working specifically with military populations. Every guide is vetted through background checks, credential reviews, reference interviews, and in-person visits where possible. We look for guides who understand moral injury, who are comfortable with the culture of service, and who know how to hold space for the kind of experiences that veterans bring into the room.

We also believe that psychedelic therapy for veterans should never be reduced to the session itself. Integration is where the insights become livable. It is where a veteran starts to make meaning from what they experienced, to connect it to their relationships, their sense of identity, and their daily life. JourneyŌM supports that process with ongoing resources and continued access to our team, not a handoff at the end of a session.

Legal Access: Where Things Stand Right Now

The legal landscape is genuinely uneven, and we want to be clear about that. Psilocybin and MDMA remain Schedule I substances under federal law, which means access outside of approved clinical trials is legally restricted in most of the country. Oregon and Colorado have established legal frameworks for supervised psilocybin use. A number of cities have decriminalized personal use. But outside those frameworks, legal options are currently limited to ketamine therapy, clinical trial enrollment, and, for some veterans, travel to countries where these therapies are legally available.

Guides in the JourneyŌM network operate within approved legal frameworks. We do not connect seekers with providers operating outside the law, and we do not facilitate access to substances in contexts where that would create legal or safety risk. What we can do is help you understand what is available to you now, where you are, and help you plan a path that is grounded in reality rather than wishful thinking.

If clinical trials are relevant to your situation, we can help you understand how to explore eligibility. If ketamine therapy is appropriate as a starting point, we can connect you with guides experienced in that work. If your circumstances and goals point toward a different path, we will tell you that honestly, even if it is not what you were hoping to hear.

A Note on Safety

Psychedelic therapy is not appropriate for everyone. There are contraindications, including certain cardiac conditions, personal or family history of psychosis, and interactions with specific medications, that require careful screening before any substance-based work begins. Veterans who are in acute crisis or who have active suicidal ideation should connect with crisis support resources first, not a psychedelic guide.

We take readiness seriously. Our free Psychedelic Readiness Assessment exists precisely to help people think clearly about whether this path is appropriate for them before they make any commitments. If the assessment raises concerns, we will say so directly. That is what safety-first guidance looks like in practice.